Nolla Derm’s overseeing physician, Zaid Fadul, MD, FS, FAAFP, discusses the revolutionary AI technology that could transform how health care conducts prescribing practices.
|Articles|June 6, 2008
Specialty pharmacies selected for Cinryze, which is poised for approval
Lev Pharmaceuticals names three companies to dispense Cinryze when it is approved.
Advertisement
Because a Food & Drug Administration advisory committee has given approval to Lev Pharmaceuticals’ Cinryze [C1 inhibitor, (human)}, the New York company is getting ready for its final approval and distribution.
Advertisement
Related to this article
As COVID-19 vaccine guidance shifts, new data suggest vaccinated patients face no greater clot or death risk than with other respiratory infections.
Alyssa Eisenberg, PharmD, explores technology’s emerging role in the health care environment and how the pharmacist of the future’s day-to-day tasks might evolve.
In the final portion of our discussion with Kimberly Kue-Tsemo, PharmD, she explores the key developments that could be the most significant push toward reducing pharmacy deserts.
In the second part of our interview with a collection of pharmacists from various backgrounds, they delve into the current developments highlighting the future of the profession.
Phase 2 trial results for the investigational vaccine were presented at IDWeek 2026 in Washington, DC, as the phase 3 program is currently underway.
The finalized rule is another step in the right direction for pharmacies calling for reform due to underwater reimbursement and other PBM pressures.
Allison Schneider, MPH, provides a detailed update regarding pharmacies’ impact within Medicare price negotiations and the legislation further impacting businesses.
Advertisement
Advertisement
Trending on Drug Topics
1
COVID-19 Vaccine Lowers Venous Thromboembolism, Mortality Risk
2
PBMs Must Now Disclose Fees to Employer Plans Under Final DOL Rule
3
American Pharmacists Month: Pharmacists as Care Team Partners Fuels Optimism for the Profession
4
Pharmacies Face Persistent MFP Cash Crunch Amid PBM, 340B Shifts
5